Triazole MRGPRD Modulators for Selective Pain Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The function of Mas-related G-protein coupled receptor D (MRGPRD) in various tissues and its role in pain signaling, gastrointestinal tract disorders, cardiovascular dysregulation, and other physiological and pathophysiological processes remains elusive, limiting effective therapeutic interventions.
Innovation Solution
Development of modulator compounds targeting MRGPRD, including specific structures and pharmaceutical compositions, to interact with the receptor as inverse agonists or antagonists, thereby modulating its activity and treating associated conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If modulator compounds are developed to target MRGPRD, then therapeutic effectiveness is improved, but compound complexity and development difficulty increase
Solution Approach 1:
The patent systematically modifies molecular parameters of the compound structure, including substituting hydrogen atoms at specific positions (R1-R9) with various chemical groups (halogen, hydroxyl, amino, carbonyl, etc.), changing ring sizes (y=0-5), and adjusting chain lengths (m, n, p values). These parameter changes enable optimization of binding affinity and selectivity for MRGPRD while maintaining manageable synthesis complexity through systematic variation rather than entirely new molecular designs.
Solution Approach 2:
The compound structure is divided into distinct functional segments: a core triazole ring system (positions 1-4), substitutable side chains (R1-R9 at various positions), and variable chain lengths (m, n, p parameters). This segmentation allows independent optimization of each segment's contribution to receptor binding and biological activity, facilitating rational drug design and reducing overall development complexity through modular assembly.
2Reliability
If selective modulators are designed to interact with MRGPRD, then therapeutic specificity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent introduces local functional groups at specific positions (R1-R9) of the molecule to achieve selective interaction with MRGPRD. Each position can be independently substituted with groups having specific properties (electron-donating, electron-withdrawing, hydrogen-bonding capabilities) to fine-tune binding affinity and selectivity. This localized modification approach maintains overall manufacturing simplicity while achieving high therapeutic specificity through targeted chemical features.
3Adaptability or versatility
If multiple compound structures are developed for different indications, then therapeutic versatility is improved, but development time increases
Solution Approach 1:
The patent creates a universal compound platform where the core triazole structure serves as a common scaffold for multiple therapeutic indications. By varying parameters m, n, p and substituting groups at R1-R9 positions, the same basic molecular framework can be adapted for different diseases (pain, gastrointestinal disorders, cardiovascular conditions, cancer) without requiring entirely new drug discoveries. This multi-functionality approach reduces development time by leveraging structure-activity relationship knowledge across indications.
Data Source
AI summary
Provided is a compound having the structure of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, m, n, p, and y are as defined herein, for use in methods for modulating MRGPRD or for treating a MRGPRD dependent condition. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.